CKCheol-Ho Kim

Cheol-Ho Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cheol-Ho Kim has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Managing hypertension, diabetes, and dyslipidemia in frail older adults

    by Jung-Yeon Choi, Cheol-Ho Kim, Kwang-Il Kim

    As the population ages, the prevalence of chronic conditions, such as hypertension, type 2 diabetes, and dyslipidemia, is rapidly increasing, particularly among frail older adults. These conditions share common pathophysiological mechanisms and substantially contribute to the development of atherosclerotic cardiovascular disease. Effective management is essential for reducing cardiovascular risk; however, older adults present unique challenges, including multimorbidity, polypharmacy, cognitive decline, and functional impairment. Frailty further complicates clinical decision-making and necessitates individualized treatment strategies. This review examines current evidence and clinical guidelines for managing hypertension, diabetes, and dyslipidemia in older adults, with a focus on frailty status. It highlights the importance of assessing functional capacity and life expectancy and prioritizing treatments with favorable risk–benefit profiles. Specific recommendations are discussed according to frailty status, including when to initiate or deintensify therapy. Ultimately, a person-centered, geriatric-informed approach is critical to optimize outcomes and preserve quality of life in this vulnerable population.


  • Open Access

    Multiple domain resilience components and frailty, postoperative complications, and one year quality of life deterioration after pancreatectomy in older patients

    by Jung-Yeon Choi, Yoo-Seok Yoon, Kwang-Il Kim, Cheol-Ho Kim

    The number of older adults is growing rapidly worldwide, and many surgical diseases are prevalent in this population. Resilience, the ability to adapt positively to adversity, remains a multisystemic process with no standardized objective measurement methods. The aim of this study was to identify the association between resilience components and frailty, postoperative complications, and quality of life changes after pancreatectomy in older patients. This study evaluated older patients (aged ≥ 65) scheduled for pancreatectomy between August 2020 and December 2023. Patients who underwent a Comprehensive Geriatric Assessment and signed informed consent were included. Frailty was determined by multidimensional frailty score more than 5. Neurohumoral resilience was measured using the ACTH stimulation test, cardiovascular autonomic function using orthostatic blood pressure measurement, and cognitive-motor function using dual-task gait tests. The primary outcome was postoperative complications, and the secondary outcome was the deterioration in quality of life one year after pancreatectomy. A total of 57 patients were included in the analysis. Among them, 17 (29.8%) were classified as frail, 10 patients (17.5%) experienced postoperative complications, and 12 patients (24.5%) had worsened quality of life after one year. Low blood pressure and slow usual gait speed was associated with frailty. Diminished cortisol responsiveness correlated with frailty and postoperative complications. Quality of life deterioration was associated with differences between dual-task (serial 7) gait speed and fast gait speed. This study highlights the potential association between multidomain resilience components, frailty, and clinical outcomes in older patients undergoing pancreatectomy. Future research should focus on developing robust, objective, and reliable resilience metrics for clinical use.


  • Open Access

    Prediction of 5-Year Survival Rate After Hip Fracture Surgery Using a Comprehensive Geriatric Assessment-Based Frailty Score Model

    by Jung-Yeon Choi, Jung-Wee Park, Kwang-Il Kim, Young-Kyun Lee, Cheol-Ho Kim

    Choi JY, et al. J Korean Med Sci. 2024 Dec;40:e40. https://doi.org/10.3346/jkms.2025.40.e40


  • Open Access

    Characteristics According to Frailty Status Among Older Korean Patients With Hypertension

    by Jung-Yeon Choi, Hae-Young Lee, Ju-Hee Lee, Youjin Hong, Sue K. Park, Dong Ryeol Ryu, Jang Hoon Lee, Seokjae Hwang, Kye Hun Kim, Sun Hwa Lee, et al.

    Choi JY, et al. J Korean Med Sci. 2024 Feb;39(10):e84. https://doi.org/10.3346/jkms.2024.39.e84


  • Open Access

    Home blood pressure monitoring: a position statement from the Korean Society of Hypertension Home Blood Pressure Forum

    by Sang-Hyun Ihm, Jae-Hyeong Park, Jang Young Kim, Ju-Han Kim, Kwang-Il Kim, Eun Mi Lee, Hae-Young Lee, Sungha Park, Jinho Shin, Cheol-Ho Kim

    Home blood pressure measurement (HBPM) has the advantage of measuring blood pressure (BP) multiple times over a long period. HBPM effectively diagnoses stress-induced transient BP elevations (i.e., white coat hypertension), insufficient BP control throughout the day (i.e., masked hypertension), and even BP variability. In most cases, HBPM may increase self-awareness of BP, increasing the compliance of treatment. Cumulative evidence has reported better improved predictive values of HBPM in cardiovascular morbidity and mortality than office BP monitoring. In this position paper, the Korean Society of Hypertension Home Blood Pressure Forum provides comprehensive information and clinical importance on HBPM.


  • Open Access

    A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study

    by Sang-Ho Jo, Seok Min Kang, Byung Su Yoo, Young Soo Lee, Ho Joong Youn, Kyungwan Min, Jae Myung Yu, Hyun Ju Yoon, Woo Shik Kim, Gee Hee Kim, et al.

    Background: This study was a multicenter, randomized, double-blinded, placebo-controlled phase III clinical trial to investigate the efficacy and safety of an olmesartan/amlodipine single pill plus rosuvastatin combination treatment for patients with concomitant hypertension and dyslipidemia. Methods: Patients with both hypertension and dyslipidemia aged 20–80 were enrolled from 36 tertiary hospitals in Korea from January 2017 to April 2018. Patients were randomized to three groups in a 1:1:0.5 ratio, olmesartan/amlodipine single pill plus rosuvastatin (olme/amlo/rosu) or olmesartan plus rosuvastatin (olme/rosu) or olmesartan/amlodipine single pill (olme/amlo) combination. The primary endpoints were change of sitting systolic blood pressure (sitSBP) from baseline in the olme/amlo/rosu vs. olme/rosu groups and the percentage change of low-density lipoprotein cholesterol (LDL-C) from baseline in the olme/amlo/rosu vs. olme/amlo groups after 8 weeks of treatment. Results: A total of 265 patients were randomized, 106 to olme/amlo/rosu, 106 to olme/rosu and 53 to olme/amlo groups. Baseline characteristics among the three groups did not differ. The mean sitSBP change was significantly larger in the olme/amlo/rosu group with −24.30 ± 12.62 mmHg (from 153.58 ± 10.90 to 129.28 ± 13.58) as compared to the olme/rosu group, −9.72 ± 16.27 mmHg (from 153.71 ± 11.10 to 144.00 ± 18.44 mmHg). The difference in change of sitSBP between the two groups was −14.62± 1.98 mmHg with significance (95% CI −18.51 to −10.73, p < 0.0001). The mean LDL-C reduced significantly in the olme/amlo/rosu group, −52.31 ± 16.63% (from 154.52 ± 30.84 to 72.72 ± 26.08 mg/dL) as compared to the olme/amlo group with no change, −2.98 ± 16.16% (from 160.42 ± 32.05 to 153.81 ± 31.57 mg/dL). Significant difference in change was found in LDL-C between the two groups with −50.10 ± 2.73% (95% CI −55.49 to −44.71, p < 0.0001). Total adverse drug reaction rates were 10.48%, 5.66% and 3.7% in the olme/amlo/rosu, olme/rosu and olme/amlo groups, respectively with no statistical significance among the three groups. Serious adverse drug reactions did not occur. Conclusions: Olmesartan/amlodipine single pill plus rosuvastatin combination treatment for patients with both hypertension and dyslipidemia is effective and safe as compared to either olmesartan plus rosuvastatin or olmesartan plus amlodipine treatment.


  • Open Access

    CHA2DS2-VASc score, cerebral small vessel disease, and frailty in older patients with atrial fibrillation

    by Jung-Yeon Choi, Leonard Sunwoo, Sun-Wook Kim, Kwang-Il Kim, Cheol-Ho Kim

    The CHA2DS2-VASc score is a validated predictor of ischemic stroke in atrial fibrillation (AF) patients. However, data are limited on whether the CHA2DS2-VASc score is associated with subclinical brain structural changes or physical frailty among older AF patients. We assessed the relationship between CHA2DS2-VASc scores and brain structural changes or physical frailty in AF patients without history of stroke. Overall, 117 patients completed a comprehensive geriatric assessment for physical frailty. In brain magnetic resonance imaging sub-study (n = 49), brain volume and white matter hyperintensity lesion burden were automatically quantified using the LESIONQUANT software program. Patients with high risk of CHA2DS2-VASc scores (≥ 2 in men or ≥ 3 in women) tended to be older and had more comorbidities, higher frailty index, and slower gait speed. Total white matter hyperintensity lesion burden was higher in those with high risk of CHA2DS2-VASc score than in those with intermediate risk (score of 1 in men or 2 in women) of CHA2DS2-VASc score (1.67 [interquartile range: 0.70–3.45] vs. 0.64 [0.19–1.44],p = 0.036). Cognitive function was associated with brain volume, but gait speed was related with white matter hyperintensity lesion burden. In conclusion, we showed a positive relationship between CHA2DS2-VASc scores, white matter hyperintensity lesion burden, and physical frailty in older AF patients. Subclinical brain changes associated with high CHA2DS2-VASc scores may predict physical frailty risk.


  • Open Access

    Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicenter, Phase III Study

    by Soon Jun Hong, Han Saem Jeong, Seung Hwan Han, Ki Yuk Chang, Bum Kee Hong, Bong Ki Lee, Shung Chull Chae, Woo Shik Kim, Chang Gyu Park, Jung Ho Heo, et al.


  • Open Access

    Is Frailty a Modifiable Risk Factor of Future Adverse Outcomes in Elderly Patients with Incident End-Stage Renal Disease?

    by Sung Woo Lee, Anna Lee, Mi-Yeon Yu, Sun-Wook Kim, Kwang-Il Kim, Ki Young Na, Dong-Wan Chae, Cheol Ho Kim, Ho Jun Chin

    Lee SW, et al. J Korean Med Sci. 2017 Nov;32(11):1800-1806. https://doi.org/10.3346/jkms.2017.32.11.1800